Top

Published in:

01-09-2010 | Review

Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

Authors: William T. Hu, Alice Chen-Plotkin, Steven E. Arnold, Murray Grossman, Christopher M. Clark, Leslie M. Shaw, Leo McCluskey, Lauren Elman, Jason Karlawish, Howard I. Hurtig, Andrew Siderowf, Virginia M.-Y. Lee, Holly Soares, John Q. Trojanowski

Published in: Acta Neuropathologica | Issue 3/2010

Abstract

Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is associated with variable sensitivity and specificity, and biomarkers can potentially improve the accuracy of clinical diagnosis. In patients suspected of having Alzheimer’s disease (AD), alterations in cerebrospinal fluid (CSF) biomarkers that reflect the neuropathologic changes of AD strongly support the diagnosis, although there is a trade-off between sensitivity and specificity due to similar changes in cognitively healthy subjects. Here, we review the current approaches in using CSF AD biomarkers (total tau, p-tau₁₈₁, and Aβ42) to predict the presence of AD pathology, and our recent work using multi-analyte profiling to derive novel biomarkers for biofluid-based AD diagnosis. We also review our use of the multi-analyte profiling strategy to identify novel biomarkers that can distinguish between subtypes of frontotemporal lobar degeneration, and those at risk of developing cognitive impairment in Parkinson’s disease. Multi-analyte profiling is a powerful tool for biomarker discovery in complex neurodegenerative disorders, and analytes associated with one or more diseases may shed light on relevant biological pathways and potential targets for intervention.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60:387–392CrossRefPubMed

Abdi F, Quinn JF, Jankovic J et al (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293–348PubMed

Amonkar SD, Bertenshaw GP, Chen TH et al (2009) Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 4:e4599CrossRefPubMed

Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2009) Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 5:325–331CrossRefPubMed

The National Institute on Aging, Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18:S1–S2CrossRef

APA (2010) DSM-5: the future of psychiatric diagnosis. APA

Apostolova LG, Hwang KS, Andrawis JP et al (2010) 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 31(8):1284–1303

Bahl JM, Heegaard NH, Falkenhorst G et al (2009) The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer’s disease. Neurobiol Aging 30:1834–1841CrossRefPubMed

Bergmann L (1965) The value of CSF-analysis in the diagnosis of MS. Acta Neurol Scand Suppl 13:559–561PubMed

10.

Bertenshaw GP, Yip P, Seshaiah P et al (2008) Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2872–2881CrossRefPubMed

11.

Bian H, Van Swieten JC, Leight S et al (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70:1827–1835CrossRefPubMed

12.

Bibl M, Mollenhauer B, Esselmann H et al (2006) CSF amyloid-beta-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain 129:1177–1187CrossRefPubMed

13.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 3:186–191CrossRefPubMed

14.

Brown MP, Grundy WN, Lin D et al (2000) Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 97:262–267CrossRefPubMed

15.

Buerger K, Ewers M, Pirttila T et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 129:3035–3041CrossRefPubMed

16.

Buerger K, Frisoni G, Uspenskaya O et al (2009) Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI). Exp Gerontol 44:579–585CrossRefPubMed

17.

Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022CrossRefPubMed

18.

Cairns NJ, Bigio EH, Mackenzie IR et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114:5–22CrossRefPubMed

19.

Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurol Res 28:155–163CrossRefPubMed

20.

Chen-Plotkin AS, Geser F, Plotkin JB et al (2008) Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 17:1349–1362CrossRefPubMed

21.

Clark CM, Xie S, Chittams J et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696–1702CrossRefPubMed

22.

Clifford DB, Fagan AM, Holtzman DM et al (2009) CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 73:1982–1987CrossRefPubMed

23.

Compta Y, Marti MJ, Ibarretxe-Bilbao N et al (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Mov Disord 24:2203–2210CrossRefPubMed

24.

Delaleu N, Immervoll H, Cornelius J, Jonsson R (2008) Biomarker profiles in serum and saliva of experimental Sjogren’s syndrome: associations with specific autoimmune manifestations. Arthritis Res Ther 10:R22CrossRefPubMed

25.

Ellis KA, Bush AI, Darby D et al (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr 21:672–687CrossRefPubMed

26.

Engelborghs S, Sleegers K, Cras P et al (2007) No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer’s disease. Brain 130:2320–2326CrossRefPubMed

27.

Fagan AM, Mintun MA, Shah AR et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer’s disease. EMBO Mol Med 1:371–380CrossRefPubMed

28.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64:343–349CrossRefPubMed

29.

Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer’s disease. Ann Neurol 61:120–129CrossRefPubMed

30.

Fleisher AS, Raman R, Siemers ER et al (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031–1038CrossRefPubMed

31.

Forman MS, Farmer J, Johnson JK et al (2006) Frontotemporal dementia: clinicopathological correlations. Ann Neurol 59:952–962CrossRefPubMed

32.

Foulds P, McAuley E, Gibbons L et al (2008) TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer’s disease and frontotemporal lobar degeneration. Acta Neuropathol 116:141–146CrossRefPubMed

33.

Fujishiro H, Ferman TJ, Boeve BF et al (2008) Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 67:649–656CrossRefPubMed

34.

Gisslen M, Krut J, Andreasson U et al (2009) Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol 9:63CrossRefPubMed

35.

Golub TR, Slonim DK, Tamayo P et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531–537CrossRefPubMed

36.

Gray H (1912) History of lumbar puncture (rachicentesis). Arch Neurol Psychiatry 6:61–69

37.

Grossman M, Farmer J, Leight S et al (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer’s disease. Ann Neurol 57:721–729CrossRefPubMed

38.

Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US (2008) Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 155:56–61CrossRefPubMed

39.

Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K (2007) Cerebrospinal fluid beta-amyloid 1–42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry 78:461–464CrossRefPubMed

40.

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844CrossRefPubMed

41.

Hodges JR, Davies RR, Xuereb JH et al (2004) Clinicopathological correlates in frontotemporal dementia. Ann Neurol 56:399–406CrossRefPubMed

42.

Hu WT, Chen-Plotkin A, Arnold SE et al (2010) Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment. Acta Neuropathol 119:669–678CrossRefPubMed

43.

Hu WT, Chen-Plotkin A, Grossman M et al (2010) Novel CSF biomarkers for frontotemporal lobar degenerations. Neurology (in press)

44.

Hu WT, Mandrekar JN, Parisi JE et al (2007) Clinical features of pathologic subtypes of behavioral-variant frontotemporal dementia. Arch Neurol 64:1611–1616CrossRefPubMed

45.

Hu WT, McMillan C, Libon DJ et al (2010) Multi-modal predictors for Alzheimer’s disease in non-fluent primary progressive aphasia. Neurology (in press)

46.

Hu WT, Seelaar H, Josephs KA et al (2009) Survival profiles of patients with frontotemporal dementia and motor neuron disease. Arch Neurol 66:1359–1364CrossRefPubMed

47.

Innogenetics. INNO-BIA AlzBio3

48.

Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128CrossRefPubMed

49.

Kasuga K, Tokutake T, Ishikawa A et al (2010) Differential levels of alpha-synuclein, beta-amyloid42, tau in CSF between patients with dementia with Lewy bodies, Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81:608–610CrossRefPubMed

50.

Koster MP, Pennings JL, Imholz S et al (2009) Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. Prenat Diagn 29:857–862CrossRefPubMed

51.

Ladogana A, Sanchez-Juan P, Mitrova E et al (2009) Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 256:1620–1628CrossRefPubMed

52.

Lewczuk P, Beck G, Ganslandt O et al (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409:1–4CrossRefPubMed

53.

Lippa CF, Duda JE, Grossman M et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819CrossRefPubMed

54.

Lui JK, Laws SM, Li QX et al (2010) Plasma amyloid-beta as a biomarker in Alzheimer’s disease: the AIBL Study of Aging. J Alzheimers Dis 20(4):1233–1242

55.

Mattsson N, Zetterberg H, Hansson O et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302:385–393CrossRefPubMed

56.

Miller DJ, Wang Y, Kesidis G (2008) Emergent unsupervised clustering paradigms with potential application to bioinformatics. Front Biosci 13:677–690CrossRefPubMed

57.

Mollenhauer B, Cullen V, Kahn I et al (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213:315–325CrossRefPubMed

58.

Morris JC, Roe CM, Xiong C et al (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122–131CrossRefPubMed

59.

Nettiksimmons J, Harvey D, Brewer J et al (2010) Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging 31(8):1419–1428

60.

Neumann M, Kwong LK, Lee EB et al (2009) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol 117:137–149CrossRefPubMed

61.

Ohrfelt A, Grognet P, Andreasen N et al (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450:332–335CrossRefPubMed

62.

Pang H, Zhao H (2008) Building pathway clusters from Random Forests classification using class votes. BMC Bioinform 9:87CrossRef

63.

Pennings JL, Koster MP, Rodenburg W, Schielen PC, de Vries A (2009) Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining. PLoS One 4:e8010CrossRefPubMed

64.

Portelius E, Dean RA, Gustavsson MK et al (2010) A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2:7CrossRefPubMed

65.

Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13:1359–1362CrossRefPubMed

66.

Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM (2007) Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem 53:859–865CrossRefPubMed

67.

Saeys Y, Inza I, Larranaga P (2007) A review of feature selection techniques in bioinformatics. Bioinformatics 23:2507–2517CrossRefPubMed

68.

Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ (2007) Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6:295–303CrossRefPubMed

69.

Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413CrossRefPubMed

70.

Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid beta 1-42 predicts cognitive decline in Parkinson’s disease. Ann Neurol (in press)

71.

Steinacker P, Hendrich C, Sperfeld AD et al (2008) TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 65:1481–1487CrossRefPubMed

72.

Steinacker P, Mollenhauer B, Bibl M et al (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370:36–39CrossRefPubMed

73.

Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43:1690–1692PubMed

74.

Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24:118–124CrossRefPubMed

75.

Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567–6572CrossRefPubMed

76.

Trojanowski JQ, Vandeerstichele H, Korecka M et al (2010) Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjects. Alzheimers Dement 6:230–238CrossRefPubMed

77.

Uc EY, McDermott MP, Marder KS et al (2009) Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73:1469–1477CrossRefPubMed

78.

van Eersel J, Bi M, Ke YD et al (2009) Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains. J Neural Transm 116:1243–1251CrossRefPubMed

79.

Verwey NA, van der Flier WM, Blennow K et al (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem 46:235–240CrossRefPubMed

80.

Walhovd KB, Fjell AM, Brewer J et al (2010) Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol 31:347–354

81.

Zhang H, Yu CY, Singer B (2003) Cell and tumor classification using gene expression data: construction of forests. Proc Natl Acad Sci USA 100:4168–4172CrossRefPubMed

82.

Zhang J, Sokal I, Peskind ER et al (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 129:526–529CrossRefPubMed

Title: Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease
Authors: William T. Hu
Alice Chen-Plotkin
Steven E. Arnold
Murray Grossman
Christopher M. Clark
Leslie M. Shaw
Leo McCluskey
Lauren Elman
Jason Karlawish
Howard I. Hurtig
Andrew Siderowf
Virginia M.-Y. Lee
Holly Soares
John Q. Trojanowski
Publication date: 01-09-2010
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 3/2010
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-010-0723-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Contribution of systemic inflammation to chronic neurodegeneration

Welcome to ICN 2010

Muscular dystrophies: an update on pathology and diagnosis

The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia

Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease

Announcing the winner of the 2010 Kurt Jellinger Prize